Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Phase II, Open-label Clinical Trial of Intranasal Ketamine for Depression in Patients With Cancer Receiving Palliative Care (INKeD-PC Study)

To see complete record on, please visit this link

Id: NCT03410446

Organisation Name: University Health Network, Toronto

Overal Status: Completed

Start Date: July 16, 2018

Last Update: May 6, 2022

Lead Sponsor: University Health Network, Toronto

Brief Summary: This is a phase 2 study of the drug ketamine for the treatment of depression in cancer patients receiving palliative care. The purpose of this study is to see how useful the drug is at decreasing the severity of depression these patients. Ketamine will be given through the nose.

  • Depression
  • Cancer
  • Palliative Care

Total execution time in seconds: 0.33557105064392